Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
Related Content
-
The University of North Carolina Comprehensive Sickle Cell ProgramTo carry out basic, translational and cl...
-
Cecelia R. Valrie, PhDDr. Cecelia Valrie is a developmental-he...
-
Onyinye Onyekwere, MDDr. Onyinye Onyekwere is a pediatric hem...
-
Piedmont Health Services and Sickle Cell AgencyPiedmont Health Services and Sickle Cell...
-
Healthy red blood cells owe their shape to muscle-like structuresRed blood cells are on a wild ride. As t...
-
Social-Environmental Factors and Cognitive and Behavioral Functioning in Pediatric Sickle Cell DiseaseSickle cell disease (SCD), an inherited ...
-
Disability evaluation under social security (hematological disorders – childhood)A. What hematological disorders do we ev...